16.04.2015 • NewsManufacturingRentschler BiopharmaGE

GE Healthcare Life Sciences and Rentschler Mark Handover

GE Healthcare Life Sciences has handed over its 1000th ÄKTAprocess to Rentschler Biotechnologie for use in the expanded biopharmaceutical manufacturing capabilities Rentschler has established in Laupheim, Germany.

The equipment supplied by GE features an automated process and manufacturing scale chromatography system. The offshoot of the US conglomerate said its biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess, which will be used in the reactor, all play a key role in Rentschler's new single-use manufacturing line.

Peter Rogge, vice president of USP Production at Rentschler, said the new line "will further enhance our ability to deliver high quality projects for companies around the globe," adding that the GE technology is also enabling an increase in Europe of next-generation manufacturing capabilities.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read